COST-EFFECTIVENESS OF LEVOFLOXACIN INHALATION SOLUTION VS. AZTREONAM INHALATION SOLUTION IN CYSTIC FIBROSIS PATIENTS IN BELGIUM

Author(s)

Medic G, Westen M, Wille M, Hemels M
Raptor Pharmaceuticals Europe B.V., Utrecht, The Netherlands

Presentation Documents

PND42--strong-u-medic-g-u-strong-westen-m-wille-m-hemels-m-br-raptor-pharmaceuticals-europe-b-v-utrecht-the-netherlands

OBJECTIVES: To conduct an economic evaluation of levofloxacin inhalation solution (LIS) compared to aztreonam lysine inhalation solution (AZLI) in Belgium for the treatment of chronic Pseudomonas aeruginosa lung infection in adult cystic fibrosis (CF) patients. METHODS:

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PND42

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Neurological Disorders

Explore Related HEOR by Topic

Economic Evaluation

Presentation